Proactive Investors - Run By Investors For Investors

Cello boss Mark Scott says health business is in “exactly the right place”

Stocktube caught up with Cello Group plc (LON:CLL) after its interim trading update dismissed any noticeable Brexit impact and promised strong full-year results in line with expectations.
“The full year we believe will be a good strong year for Cello Health, as it has been for a number of years, and as we hope it will continue to be,” chief executive Mark Scott said.
“Strategically it is in exactly the right place, in a growth market, and our franchise is growing strongly particularly in the [United] States.”
Scott also talks about restructuring within Cello’s businesses and the benefits of being a US market-centric biopharma business in Brexit Britain. Customers of the Cello Health unit are ‘globally focussed’, he added.

Meet Location Sciences Group PLC, Itaconix Plc, Shield Therapeutics PLC and WideCells Group at our event, London , 21 March 2019. Register here »
View full CLL profile View Profile

Cello Health plc Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use